Cosmo Pharmaceuticals Methylene Blue MMX regulatory update:

Substantial alignment reached with FDA on second phase III study features - next steps

Dublin, Ireland - January 21, 2020 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today provided a regulatory update for Methylene Blue MMX, an investigational new drug product developed as an aid for the detection of colorectal lesions in patients undergoing routine screening and surveillance of colonoscopies.

In a face-to-face meeting with the U.S. Food and Drug Administration (FDA), the company received positive feedback and achieved substantial alignment on the proposed trial design and endpoints of the second Phase III protocol and associated statistical analysis plan. This alignment is reflected in the minutes received from the FDA. The next step will be the submission of the complete protocol and statistical analysis plan (expected in Q1 2020) for final comment by the FDA before the start of the trial, which Cosmo hopes to begin within H1 2020.

Cosmo will promptly provide updates on the process and remains fully committed to bringing this potential improvement to existing standards of care for colonoscopy screening and surveillance to the health care system as soon as possible. Effective screening and surveillance are critical to the prevention of colorectal cancer and the reduction in the overall incidence of life-threatening colorectal cancer.


Media release (PDF)



Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50